HomeNewsMarket

Laborate's Aqualab Eyes INR 250 Crore with Retail-First Model by FY 25-26

Laborate's Aqualab Eyes INR 250 Crore with Retail-First Model by FY 25-26

Aqualab, the direct-to-retail division of Laborate Pharmaceuticals India, has crossed the INR 100 crore revenue mark within three years of launch and now expects to touch INR 250 crore by FY 2025–26. The growth has been driven by an expanding portfolio of over 800 SKUs and a network of over 500 retail stockists, with tier-II and tier-III markets contributing a rising share of sales.

Since its inception in 2022, the division has reported consistent year-on-year growth, moving from INR 76 crore in FY 2022–23 to INR 108 crore in FY 2023–24. Aqualab has also focused on ensuring affordability and last-mile access, enabling its medicines to reach smaller towns alongside metropolitan centres.

“Crossing INR 100 crore in three years demonstrates how quickly the Direct-to-Retail model is scaling in India. We are now targeting INR 250 crore by FY 2025-26, with non-metro markets expected to contribute 42 percent of incremental growth. Expanding therapeutic categories and strengthening the last-mile delivery will remain our key focus areas,” said Arpit Bhatia, Managing Director, Laborate Pharmaceuticals.

Aqualab’s rise is in step with national priorities such as Make in India and the government’s PLI push to boost domestic pharma manufacturing. The retail pharmacy market, pegged at INR 18,700 crore in FY24, is projected to touch INR 31,200 crore by FY32, growing at a Compound Annual Growth Rate (CAGR) of 6.6 percent on the back of stronger generic penetration, greater health awareness and organised distribution. Leveraging this momentum, Aqualab is preparing to expand into new categories, add facilities, adopt digital channels and explore exports, consolidating its position in India’s retail pharma landscape.

Laborate’s WHO, GMP and EU GMP-certified facilities have provided Aqualab with the infrastructure to scale rapidly while maintaining international quality standards. The company operates modern plants with advanced manufacturing and quality control systems, enabling compliance with stringent benchmarks. This foundation has not only supported Aqualab’s domestic expansion, but it also positions the division for potential export opportunities in the future.

More news about: market | Published by Dineshwori | August - 27 - 2025

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members